Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ4 | P56696 | 3/20 | 0.42 |
| ▸ | KCNQ5 | Q9NR82 | 3/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.40 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
| ▸ | CTSS | P25774 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 1/20 | 0.37 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.36 |
| ▸ | ELANE | P08246 | 3/20 | 0.36 |
| ▸ | RORC | P51449 | 3/20 | 0.35 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5538920 | 0.87 | KCNQ4 (0.47) | KCNQ4KCNQ5NPSR1CYP17A1MAPK14 | |
| SCHEMBL4715108 | 0.86 | KCNQ4 (0.45) | KCNQ4KCNQ5CYP17A1P2RX3MAPK14 | |
| SCHEMBL13537168 | 0.80 | NPSR1 (0.42) | NPSR1CYP17A1P2RX3CNR2CTSS | |
| SCHEMBL345692 | 0.80 | NPSR1 (0.40) | KCNQ4KCNQ5NPSR1CYP17A1P2RX3 | |
| SCHEMBL344039 | 0.79 | NPSR1 (0.48) | NPSR1GRM2 | |
| SCHEMBL344043 | 0.77 | NPSR1 (0.49) | NPSR1CNR2GRM2 | |
| SCHEMBL4900478 | 0.77 | AAK1 (0.47) | P2RX3AAK1 | |
| SCHEMBL12358957 | 0.76 | CYP17A1 (0.44) | CYP17A1CNR2MAPK14 | |
| SCHEMBL1593857 | 0.76 | NPSR1 (0.48) | NPSR1CNR2GRM2 | |
| SCHEMBL13851061 | 0.76 | BRD4 (0.42) | NPSR1CYP17A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2321319-B1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES INC (US) | 2012-03-14 | — | — | EP | disclosed |
| US-7998950-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2011-08-16 | — | — | US | disclosed |
| US-7998950-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2011-08-16 | — | — | US | disclosed |
| US-20100022508-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2010-01-28 | — | — | US | disclosed |
| US-20100022508-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022508-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | KCNQ4 4220/4885KCNQ5 4104/4885NPSR1 4462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.